page-decoration REQUEST A REPRESENTATIVE

Once-at-bedtime LUMRYZ has an extended-release formulation to avoid middle-of-the-night dosing1,2

LUMRYZ delivers therapeutic exposure over the course of patients’ nocturnal sleep period.2

Medication concentration over time graphic Medication concentration over time graphic

© 2022 The Authors. Published by Elsevier B.V. This is an open-access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

The phase 1 study was designed to evaluate the relative bioavailability, safety, and tolerability of LUMRYZ compared to twice-nightly sodium oxybate.2

This study found similar geometric least squares mean concentration at ~8 hours after the first and only dose of LUMRYZ, compared to 8 hours after the first dose of twice-nightly sodium oxybate when the second dose is given 4 hours later.2

Bogan study designpop up icon

Each premeasured packet contains a proprietary blend of immediate-release and controlled-release granules1,3

granules chart

GHB, gamma-hydroxybutyrate; SE, standard error.

References:

  1. References: 1. LUMRYZ (sodium oxybate for extended-release oral suspension). Prescribing Information. Chesterfield, MO: Avadel Pharmaceuticals. 2. Bogan R, Thorpy MJ, Winkelman JW, et al. Randomized, crossover, open-label study of the relative bioavailability and safety of FT218, a once-nightly sodium oxybate formulation: phase 1 study in healthy volunteers. Sleep Med. 2022;100:442-447. 3. Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):1-11.